Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,518 questions in 135 reviews · Infectious Diseases

current versions

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR Hand‐washing behavioural changes/changes in knowledge, attitude and practice · adults with AIDS Hand‐washing promotion for preventing diarrhoea (2021) · Cochrane	no estimate extracted	1 study · 1 participants	Moderate
Atovaquone‐proguanil vs artemether‐lumefantrine Total failure day 28 PCR‐adjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 5 [0.25, 99.95]	1 study · 60 participants	Low
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil Total failure day 28 PCR‐unadjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 15.48 [0.9, 267.27]	1 study · 187 participants	Low
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil Total failure [day 42 PCR‐adjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 1.84 [0.95, 3.56]	2 studies · 1258 participants	Moderate
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil Total failure day 42 PCR‐unadjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 1.56 [0.88, 2.79]	1 study · 1063 participants	Moderate
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil Early treatment failure · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 5.11 [0.25, 104.94]	2 studies · 395 participants	Low
Atovaquone‐proguanil vs artemether‐lumefantrine Total failure day 42 PCR‐unadjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 5 [0.25, 99.95]	1 study · 60 participants	Low
Atovaquone‐proguanil vs artemether‐lumefantrine Total failure day 42 PCR‐adjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 3 [0.19, 47.12]	1 study · 208 participants	Low
Atovaquone‐proguanil vs artesunate‐amodiaquine Total failure day 28 PCR‐adjusted · children under the age of 5 years Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 3.19 [0.67, 15.22]	1 study · 132 participants	Low
Atovaquone‐proguanil vs artesunate‐amodiaquine Total failure day 28 PCR‐unadjusted · children under the age of 5 years Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 1.2 [0.49, 2.91]	1 study · 132 participants	Low
Atovaquone‐proguanil vs artesunate‐amodiaquine Early treatment failure · children under the age of 5 years Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 13.8 [0.79, 240.11]	1 study · 132 participants	Low
Atovaquone‐proguanil vs artesunate‐mefloquine Total failure day 42 PCR‐adjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 1.15 [0.57, 2.34]	2 studies · 1168 participants	High
Atovaquone‐proguanil vs artesunate‐mefloquine Total failure day 42 PCR‐unadjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 0.8 [0.5, 1.3]	1 study · 1063 participants	Low
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil Total failure day 28 PCR‐adjusted · children and adults Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (2021) · Cochrane	RR 5.143 [0.61, 43.52]	2 studies · 375 participants	Low
Rotarix vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.07 [0.03, 0.18]	4 studies · 14976 participants	High
Rotarix vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.64 [0.52, 0.79]	2 studies · 26479 participants	High
Rotarix vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.74 [0.5, 1.09]	2 studies · 23317 participants	Low
Rotarix vs placebo All‐cause death · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 1.27 [0.89, 1.81]	9 studies · 77043 participants	Moderate
Rotarix vs placebo All serious adverse events · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.85 [0.76, 0.95]	9 studies · 77069 participants	High
Rotarix vs placebo Serious adverse events: intussusception · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.72 [0.39, 1.32]	6 studies · 75540 participants	Low
Rotarix vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.42 [0.28, 0.61]	4 studies · 15822 participants	High
Rotarix vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.65 [0.51, 0.83]	2 studies · 13768 participants	Moderate
Rotarix vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.73 [0.56, 0.95]	2 studies · 5639 participants	High
Rotarix vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.83 [0.72, 0.96]	1 study · 2764 participants	High
Rotarix vs placebo All‐cause death · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.88 [0.63, 1.21]	11 studies · 8374 participants	Moderate
Rotarix vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.1 [0.07, 0.14]	6 studies · 18145 participants	High
Rotarix vs placebo All serious adverse events · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.9 [0.77, 1.05]	10 studies · 7674 participants	High
Rotarix vs placebo Serious adverse events: intussusception · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 1.49 [0.06, 36.63]	5 studies · 17068 participants	Low
RotaTeq vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.03 [0.01, 0.11]	5 studies · 7688 participants	High
RotaTeq vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.04 [0.01, 0.11]	2 studies · 5442 participants	High
RotaTeq vs placebo Severe all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	no estimate extracted	NR	No studies
RotaTeq vs placebo Severe all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	no estimate extracted	NR	No studies
RotaTeq vs placebo All‐cause death · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 1.24 [0.69, 2.22]	6 studies · 72654 participants	Low
RotaTeq vs placebo All serious adverse events · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.92 [0.84, 1.01]	5 studies · 70690 participants	High
RotaTeq vs placebo Serious adverse events: intussusception · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.69 [0.35, 1.38]	9 studies · 73925 participants	Low
RotaTeq vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	no estimate extracted	NR	No studies
Rotarix vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.48 [0.37, 0.61]	1 study · 3874 participants	Moderate
RotaTeq vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.21 [0.11, 0.41]	1 study · 3863 participants	Low
RotaTeq vs placebo Severe all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	no estimate extracted	NR	No studies
RotaTeq vs placebo Severe all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	no estimate extracted	NR	No studies
RotaTeq vs placebo All‐cause death · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.33 [0.01, 8.18]	2 studies · 4088 participants	Very low
RotaTeq vs placebo All serious adverse events · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.66 [0.14, 3.17]	2 studies · 4082 participants	Very low
RotaTeq vs placebo Serious adverse events: intussusception · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 5.01 [0.24, 104.29]	2 studies · 4082 participants	Very low
RotaTeq vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.43 [0.29, 0.64]	2 studies · 6775 participants	High
RotaTeq vs placebo Severe cases of rotavirus diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.56 [0.41, 0.77]	2 studies · 6744 participants	High
RotaTeq vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.8 [0.58, 1.11]	1 study · 4085 participants	Moderate
RotaTeq vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.85 [0.74, 0.99]	2 studies · 5977 participants	High
Rotarix vs placebo Severe cases of all‐cause diarrhoea · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.49 [0.4, 0.6]	2 studies · 6269 participants	Moderate
RotaTeq vs placebo All‐cause death · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.91 [0.68, 1.23]	3 studies · 7706 participants	Moderate
RotaTeq vs placebo All serious adverse events · children Vaccines for preventing rotavirus diarrhoea: vaccines in use (2021) · Cochrane	RR 0.99 [0.72, 1.36]	4 studies · 7730 participants	Moderate